XML 14 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated statements of stockholders' equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Balance at Dec. 31, 2023 $ 159,565 $ 5 $ 561,433 $ (24) $ (401,849)
Balance, Shares at Dec. 31, 2023   45,918,233      
Unrealized gain on marketable securities 24     24  
Stock-based compensation 5,410   5,410    
Issuance of common stock upon exercise of stock options 250   250    
Issuance of common stock upon exercise of stock options, Shares   79,682      
Issuance of common stock related to employee stock purchase plan 168   168    
Issuance of common stock related to employee stock purchase plan, Shares   37,542      
Issuance of vested restricted stock units and performance stock units, Shares   190,350      
Shares sold as part of controlled equity offering sales agreement, net of commissions 1,299   1,299    
Shares sold as part of controlled equity offering sales agreement, net of commissions, Shares   272,270      
Net Income (Loss) (26,374)       (26,374)
Balance at Mar. 31, 2024 140,342 $ 5 568,560   (428,223)
Balance, Shares at Mar. 31, 2024   46,498,077      
Balance at Dec. 31, 2024 229,021 $ 5 719,997 (151) (490,830)
Balance, Shares at Dec. 31, 2024   54,032,826      
Unrealized gain on marketable securities 47     47  
Stock-based compensation 6,753   6,753    
Issuance of common stock upon exercise of stock options 1,004   1,004    
Issuance of common stock upon exercise of stock options, Shares   214,996      
Issuance of common stock related to employee stock purchase plan 370   370    
Issuance of common stock related to employee stock purchase plan, Shares   39,467      
Issuance of vested restricted stock units and performance stock units, Shares   308,425      
Net Income (Loss) 112,879       112,879
Balance at Mar. 31, 2025 $ 350,074 $ 5 $ 728,124 $ (104) $ (377,951)
Balance, Shares at Mar. 31, 2025   54,595,714